

DELIVERABLE 3.1 ERN-EUROBLOODNET EVALUATION PLAN

European Reference Network on Rare Hematological Diseases ERN-EuroBloodNet

EUROPEAN REFERENCE NETWORKS
FOR RARE, LOW PREVALENCE AND COMPLEX DISEASES

Share. Care. Cure.



DOCUMENT INFORMATION

DELIVERABLE 3.1 ERN-EUROBLOODNET EVALUATION PLAN

Report document

ERN: **ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases)**

Call: **EU4H-2022-ERN-IBA**

Type of action: **EU4H-PJG**

Grant Agreement Number: **101085717**

Working Package: **WP 3 Evaluation**

Task: **Task 3.1 Evaluation strategy**

Authors:

Pierre Fenaux - ERN-EuroBloodNet Coordinator

Béatrice Gulbis - ERN-EuroBloodNet Co-coordinator

Maria del Mar Mañú Pereira – ERN-EuroBloodNet Scientific Director

Victoria Gutiérrez Valle - ERN-EuroBloodNet Scientific Manager

Short Description

Report (EN) describing evaluation strategy to assess the performance of the foreseen activities, achievement of expected results and their impact on pre-defined target groups.

Disclaimer:

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

Publication Date

28//07/2022

TABLE OF CONTENTS

1. Introduction

2. Evaluation methodology

2.1 ERN-EuroBloodNet Specific Objectives and Working Packages

2.2 ERN-EuroBloodNet Set of Evaluation indicators

3. Evaluation calendar

1. INTRODUCTION

The implementation of the ERN-EuroBloodNet development and work plan requires from a strict control point on each step, ensuring the smooth running of all the tasks and the completion of defined timelines while enabling the involvement and feedback from all the stakeholders contributing to the network.

In line with “**ERN-EuroBloodNet Specific Objective 3. To ensure ERN-EuroBloodNet implementation is of high quality and completed in time**”, ERN-EuroBloodNet evaluation methodology is undertaken by “**WP3 Evaluation**” establishing the plans and methods to detect partial progress failures or weak points and allow the implementation of the necessary corrective measures needed to guarantee compliance with the work plan and the achievement of network objectives and outcomes.

This document presents the Evaluation plan for ERN-EuroBloodNet current action (1st March 2022 - 31st August 2023) based on a continuous evaluation of the Specific Objectives and Working Package (WPs) Tasks through a set of monitoring indicators. Each indicator is linked with a corresponding Task and a time plan and target value is also proposed for each one.

2. EVALUATION METHODOLOGY

In order to monitor ERN-EuroBloodNet activities in terms of performance, achievement of expected results and their impact on pre-defined target groups a first set of SMART (Specific, Measurable, Achievable, Realistic and Time-limited) indicators for each Specific Objective and Working Packages actions were identified as core of the Evaluation strategy by the time of ERN-EuroBloodNet grant proposal submission.

During the first five months of ERN-EuroBloodNet present action, the first set of indicators have been revisited by the ERN-EuroBloodNet coordination team in order to add further details and refine the set of indicators as the basis for the Evaluation strategy. The final list of indicators have been approved by the ERN-EuroBloodNet coordinator, co-coordinator and scientific director (see Section 2.2 ERN-EuroBloodNet Set of Evaluation Indicators).

ERN-EuroBloodNet Monitoring Officer will conduct biannual monitoring exercises (Month 6, 12 and 18) for the gathering of the indicators from the ERN-EuroBloodNet coordination team members involved in the Task evaluated for the period. Milestones, deliverables and indicators for the period will be compiled in an internal working document for each specific WP according to timelines defined (See Section 3. Evaluation calendar).

Progress will be assessed by ERN-EuroBloodNet Monitoring Officer together with Scientific director complemented with the periodic teleconferences with the relevant actors allowing the assessment of the implementation of network actions and alignment with objectives and expected results.

ERN-EuroBloodNet Board of the Network and Scientific and Strategic Board meetings will be crucial to ensure good delivery of objectives and cooperation among members, enhance networking across ERN-EuroBloodNet and provide a general overview of the ERN in terms of its operational progress. Dissemination activities will be key factors to reach the largest number of target groups. A survey to evaluate satisfaction of Members and Affiliated Partners with the ERN-EuroBloodNet management will be defined and conducted among representatives and substitutes as part of the Evaluation strategy.

Finally, participation of each member representatives in the different activities performed in the network will be monitored in order to assess their level of response. Less responsive members will be approached by coordination to identify the causes and facilitate their active involvement in the network.

A report gathering the evaluation results will be produced at the end of the project. (**D3.2 ERN-EuroBloodNet evaluation report**).

2.1 ERN-EUROBLOODNET SPECIFIC OBJECTIVES AND WORKING PACKAGES

ERN-EuroBloodNet's general aim for the present period of implementation is to ensure the continuation of the coordination, management and operational activities of the network enabling rare hematological disease (RHDs) patients and health professionals to benefit from pooling of expertise, knowledge and resources at the European level and to receive the appropriate diagnosis and treatment as well as enhance knowledge generation, training and research in the area of RHDs.

In line with the general objective, the following 8 Specific Objectives have been defined:

- Specific Objective 1. To maintain ERN-EuroBloodNet general coordination and management of operational activities in line with the development strategy and supporting integrated and coordinated work between Members & APs
- Specific Objective 2. To increase the outreach of ERN-EuroBloodNet actions and outcomes on RHD within the ERN and beyond by improving communication and dissemination strategies
- Specific Objective 3. To ensure that ERN-EuroBloodNet implementation is of high quality and completed in time
- Specific Objective 4. To provide inter-professional consultation of RHD complex cases by sharing of expertise and safe exchange of clinical information through the Clinical Patient Management System (CPMS)
- Specific Objective 5. To enhance equal access to highly specialized outcome-based healthcare for RHD across EU
- Specific Objective 6. To strengthen the use and re-use of RHD health data for the provision of best healthcare and for the promotion of research and innovation
- Specific Objective 7. To spread cutting-edge knowledge and facilitate continuing medical education in the field of RHDs
- Specific Objective 8. To promote best practice in prevention, diagnosis and clinical care across EU by the development and update of ERN clinical practice guidelines and other Clinical Decision Making tools

Tasks aiming to achieve ERN-EuroBloodNet Specific Objectives for the present period of implementation have been split into the following 6 Working Packages (WP):

- WP1 Coordination
- WP2 Dissemination
- WP3 Evaluation
- WP4 CPMS Activities
- WP5 Other digital activities of ERNs
- WP6 Training and education

2.2 ERN-EUROBLOODNET SET OF EVALUATION INDICATORS

WPs tasks are correlated to the Specific Objectives allowing the identification of Process / Output / Outcome indicators in order to continuously evaluate the smooth development of the action, its results and impact meanwhile enabling the promptly identification of risks/deviations and the establishment of remedial actions as follows:

- Process Indicators– in order to measure whether planned activities of a WP took place or not allowing to take remedial actions if necessary for achievement of results.
- Output Indicators - to analyse in deep the products produced and assess if the results are in line with the objectives defined. Product evaluation is directly linked to achievement of Milestones and Deliverables on due time.
- Outcome indicators – to measure the overall achievement of every specific objective of a WP

The following Set of indicators have been defined as core for ERN-EuroBloodNet Evaluation strategy.

Working Package 1: Coordination			
Specific Objective 1: To maintain ERN-EuroBloodNet general coordination and management of operational activities in line with the development strategy and supporting integrated and coordinated work between Members & APs			
Task 1.1 ERN-EuroBloodNet development activities			
1	Process	Development of the ERN-EuroBloodNet development strategy	Target value: Document for the ERN-EuroBloodnet development strategy including: a) Process for active integration of new members in the ERN environment b) Procedure for expansion of disease of expertise coverage of ERN members c) Provision of support in the evaluation process of ERN members Expected date: Mo5
2	Output	Validation of the ERN-EuroBloodNet development strategy	Target value: ERN-EuroBloodNet development strategy validated by the BoN Expected date: Mo7
3	Outcome	% of new members successfully integrated in the ERN main actions	Target value: 90% Expected date: Mo12
Task 1.2 Organization of meetings			
4	Process	Invitations for the virtual meeting for welcoming new members	Target value: 72 Expected date: Mo1
5	Output	% of HCPs participating to the virtual meeting for welcoming new members	Target value: 28 (80% of new members) Expected date: Mo1
6	Outcome	Number of actions presented during the meeting	Target value: 15 Expected date: Mo1
7	Process	Invitations to the face-to-face meeting with the Board of the Network (BoN)	Target value: 206 Expected date: Mo8
8	Output	% of HCPs participants to the face-to-face meeting with the Board of the Network (BoN)	Target value: 72 (70% of HCPs members and APs) Expected date: Mo13
9	Outcome	Number of new actions launched in the frame of the Board of the Network (BoN) meeting	Target value: At least 2 Expected date: Mo13

Work Package 2: Dissemination

Specific Objective 2: To increase the outreach of ERN-EuroBloodNet actions and outcomes on RHD within the ERN and beyond by improving communication and dissemination strategies

Task 2.1 Dissemination strategy

10	Process	Development of strategies for key processes of ERN dissemination	Target value: Description of the objectives and actions to increase awareness of ERN-EuroBloodNet goals and achievements
			Expected date: Mo3
11	Output	Development of ERN-EuroBloodNet Dissemination plan	Target value: Document: ERN-EuroBloodNet Dissemination plan
			Expected date: Mo3
12	Outcome	Increase of communication channels traffic	Target value: At least increase 5% (baseline values: Website traffic: 64.789 page views in the last year (Feb 2021-Feb2022), Twitter followers: 1154 (Feb 2022), Youtube subscribers: 262 (Feb 2022)). Total increase expected: Website traffic increase of 3239, Twitter new followers: 54, Youtube new subscribers: 13
			Expected date: Mo18

Task 2.2 Update and creation of dissemination and communication channels and materials

13	Process	Creation of 1 video on ERN-EuroBloodNet objectives and key actions addressing the general audience	Target value: Definition of content and first sketch produced
			Expected date: Mo4
14	Output	Publication of 1 video on ERN-EuroBloodNet objectives and key actions addressing the general audience	Target value: Video published at ERN-EuroBloodNet website and Youtube channel
			Expected date: Mo7
15	Outcome	Number of views of the ERN-EuroBloodNet video	Target value: 100
			Expected date: Mo18
16	Process	Proposals for upgrades on ERN-EuroBloodNet website to increase awareness of network goals and achievements	Target value: 5
			Expected date: Mo3
17	Output	Number of pages upgraded	Target value: 10
			Expected date: Mo8
18	Outcome	Increase of website traffic	Target value: 3000
			Expected date: Mo18

Task 2.3 Peer review publications

19	Process	Number of topics identified for ERN-EuroBloodNet peer review publications on transversal and specific action areas.	Target value: 3
			Expected date: Mo4
20	Output	Number of ERN-EuroBloodNet peer review publications on transversal and specific action areas published in open access	Target value: 3
			Expected date: Mo18
21	Outcome	Number of citations	Target value: 50
			Expected date: Mo18

Work Package 3: Evaluation			
Specific Objective 3. To ensure that ERN-EuroBloodNet implementation is of high quality and completed in time			
Task 3.1 Evaluation strategy			
22	Process	Definition of the survey to evaluate satisfaction of HCPs' representatives with the ERN-EuroBloodNet management	Target value: 1 Expected date: Mo9
23	Output	Number of answers received	Target value: > 80% of responders (82 of 103 HCPs) Expected date: Mo9
24	Outcome	% of positive evaluations	Target value: > 80% Expected date: Mo10
Task 3.2 Internal monitoring and evaluation			
25	Process	Identification of set of Process/Output/Outcome indicators to be collected from WP leaders and relevant actors to monitor the performance of the foreseen activities, achievement of expected results and their impact	Target value: 60 Expected date: Mo3
26	Output	Number of internal monitoring exercises gathering indicators defined in the Evaluation plan from the WP leaders and relevant actors	Target value: 3 Expected date: Mo6, 12, 18
27	Outcome	% of evaluation indicators accomplished	Target value: > 80% Expected date: Mo18

Work Package 4: CPMS activities			
Specific Objective 4. To provide inter-professional consultation of RHD complex cases by sharing of expertise and safe exchange of clinical information through the Clinical Patient Management System (CPMS)			
Task 4.1 Maintenance of the ERN-EuroBloodNet CPMS Helpdesk			
28	Process	Number of experts reached on the informative parallel session on CPMS of the face to face BoN meeting	Target value: 127 (participants to the BoN meeting) Expected date: Mo13
29	Output	Number of new experts registered from the informative parallel session on CPMS of the face to face BoN meeting	Target value: 10 Expected date: Mo14
30	Outcome	Number of closed panels in CPMS opened by the new experts registered	Target value: 5 Expected date: Mo18
Task 4.3 ERN-EuroBloodNet CPMS pilot scheme			
31	Process	Number of new CPMS Virtual Boards for the implementation of pilots for CPMS population	Target value: 2 Expected date: Mo9
32	Output	Number of experts configuring the new Virtual Boards and registered in CPMS	Target value: 40 Expected date: Mo10
33	Outcome	Number of closed panels in CPMS	Target value: 108 Expected date: Mo18

Work Package 5: Other digital activities of ERNs

Specific Objective 5. To enhance equal access to highly specialized outcome-based healthcare for RHD across EU

Task 5.2 ERNs Monitoring exercises

34	Process	Number of ERN Monitoring exercises conducted for the compilation of ERNs monitoring indicators from Members and APs	Target value: 2
			Expected date: Mo1,13
35	Output	Number of HCPs providing data	Target value: 103
			Expected date: Mo2, 14
36	Outcome	Percentage of data completion	Target value: 100%
			Expected date: Mo2, 14

Task 5.3 Mapping of Highly specialized procedures

37	Process	Number of mapping exercises for an HSP and/or very rare RHD	Target value: 1
			Expected date: Mo4
38	Output	% of responders among members and APs with expertise for the procedure covered by the mapping	Target value: 60%
			Expected date: Mo8
39	Outcome	Number of international congresses where the results from the mapping were presented	Target value: 2
			Expected date: Mo18

Task 5.4 Infopoint for patients dealing with Cross border health rights

40	Process	Online form for patients requiring assistance for cross border health rights	Target value: Definition of the structure and information required in the online form
			Expected date: Mo2
41	Output	Online form for patients requiring assistance for cross border health rights	Target value: Online form available at the ERN-EuroBloodNet website
			Expected date: Mo5
42	Outcome	Number of patients assisted through the requests compiled from online form for patients requiring assistance for cross border health rights	Target value: 10
			Expected date: Mo18

Specific Objective 6. To strength the use and re-use of RHD health data for the provision of best healthcare and for the promotion of research and innovation

Task 5.7 ENROL pilots for population scheme

43	Process	Number of modules expanding ENROL RHD Common data set defined	Target value: 2 (BPDCN and vWD)
			Expected date: Mo5
44	Output	Number of elements implemented for BPDCN and vWD modules dataset	Target value: 20 per module
			Expected date: Mo7
45	Outcome	Number of HCPs testing BPDCN and vWD modules dataset	Target value: 6
			Expected date: Mo10
46	Process	BPDCN and vWD legal Policy established with the support of ENROL	Target value: Legal and ethical documents for data processing in agreement with GDPR i.e. Transfer agreements, informed consents
			Expected date: Mo6
47	Output	BPDCN and vWD collaboration for the transfer of a subset of pseudonymised data to ENROL	Target value: Collaborations agreements signed
			Expected date: Mo8
48	Outcome	Number of countries contributing to ENROL through BPDCN and vWD pilots	Target value: 4
			Expected date: Mo18

Task 5.8 ENROL statistical data analysis

49	Process	Integration of ERN monitoring indicator "2.1 Number of new patients referred to the Health Care Providers participating in the ERN" to ENROL	Target value: Definition of the level of granularity of RHD disease groups desirable for a relevant epidemiological statistical analysis
			Expected date: Mo3
50	Output	Number of ERN-EuroBloodNet members and APs providing data to ENROL either a) RHD disease groups granularity defined through monitoring exercises, or b) pseudonymised patient level	Target value: 80
			Expected date: Mo9
51	Outcome	ENROL Statistical analysis following the Statistical plan	Target value: Epidemiological figures available at ENROL Website
			Expected date: Mo18

Work Package 6: Training and education

Specific Objective 7. To spread cutting-edge knowledge and facilitate continuing medical education in the field of RHDs

Task 6.3 Organization and development of Webinar Programs for health professionals

52	Process	Number of webinars held for health professionals	Target value: 16
			Expected date: Mo18
53	Output	Media number of participants	Target value: 75 per webinar (16 webinars expected: Total of 1200 professionals trained)
			Expected date: Mo18
		Number of countries reached	Target value: 20 European Countries and 5 Non European Countries
			Expected date: Mo18
		Number of webinars recordings published on EuroBloodNet EDU Youtube	Target value: 16
			Expected date: Mo18
56	Outcome	% Participants recommending to colleagues	Target value: 80%
			Expected date: Mo18
		% Participants Translating the knowledge learned into the management of patients	Target value: 60%
			Expected date: Mo18
		% of positive evaluations	Target value: 80%
			Expected date: Mo18
		Evaluation through Kirkpatrick methodology	Target value: 80%
			Expected date: Mo18

Task 6.4 Organization and development of Webinar Programs for Patients and advocates

59	Process	Number of webinars held for patients and patients organizations	Target value: 15
			Expected date: Mo18
60	Output	Media number of participants	Target value: 20 patients per webinar (15 webinars expected: Total of 300 patients trained)
			Expected date: Mo18
		Number of countries reached	Target value: 14 European Countries and 3 Non European Countries
			Expected date: Mo18
		Number of webinars recordings published on EuroBloodNet EDU Youtube	Target value: 15
			Expected date: Mo18
63	Outcome	%Participants disseminating the knowledge among the local patients and parents patients community	Target value: 20%
			Expected date: 18Mo
		% Participants recommending the webinar among other people living with the same rare condition	Target value:80%
			Expected date: 18Mo
		% of positive evaluations	Target value: 80%
			Expected date: Mo18
		Evaluation through Kirkpatrick methodology	Target value: 80%
			Expected date: Mo18

Task 6.5 Preceptorships for health professionals carried out on HCPs sites and coordinated by ERN-EuroBloodNet experts

66	Process	Number of hosting centers participating in the short stays	Target value: 4
			Expected date: Mo3
67	Output	Number of health professionals participating in the short stays	Target value: 10
			Expected date: Mo4
68	Outcome	% of positive evaluations	Target value: 90%
			Expected date: Mo6

Task 6.6 Co-organization with the ePAGs of Educational workshops

69	Process	Number of topics agreed for the educational workshop at ASCAT in collaboration with ePAGS	Target value: 3
			Expected date: Mo4
70	Output	Number of participants	Target value: 50
			Expected date: Mo8
71	Outcome	% of positive evaluations	Target value: 90%
			Expected date: Mo9

Specific Objective 8. To promote best practice in prevention, diagnosis and clinical care across EU by the development and update of ERN clinical practice guidelines and other Clinical Decision Making tools

Task 6.7 Public repository of RHD Guidelines and other CDMTs and search tool

72	Process	Number of CPGs and CDMTs compiled for the Bleeding-Coagulation disorders and Lymphoid subnetworks	Target value: 50
			Expected date: Mo3
73	Output	CPGs and CDMTs for the bleeding and coagulation and lymphoid subnetwork classified based on Quality Domains	Target value: 40
			Expected date: Mo5
74	Outcome	Number of CPGs and other CDMTs for Bleeding-Coagulation disorders and Lymphoid subnetworks available at ERN-EuroBloodNet repository of CPGs and other CDMTs and findable through the search tool	Target value: 40
			Expected date: Mo6

Task 6.8 Foster creation of new CPGs and other CDMTs

75	Process	Number of experts participating in Onsite consensus conference with Expert panel and patient advocate to reach final consensus of the Guidelines for Adult Burkitt Lymphoma	Target value: 10
			Expected date: Mo6
76	Output	Guidelines for Adult Burkitt Lymphoma published in an indexed journal with the endorsement of ERN-EuroBloodNet and available at ERN-EuroBloodNet repository of CPGs and other CDMTs	Target value: 1
			Expected date: Mo9
77	Outcome	Number of citations	Target value: 10
			Expected date: Mo18

Task 6.9 Creation of patients' pathways & patients' summary

78	Process	Number of patients involved in the creation of patients' pathway	Target value: 10
			Expected date: Mo6
79	Output	Patients' pathway published in an indexed journal with the endorsement of ERN-EuroBloodNet and available at ERN-EuroBloodNet repository of CPGs and other CDMTs	Target value: 1
			Expected date: Mo15
80	Outcome	Number of citations	Target value: 5
			Expected date: Mo18

3. EVALUATION CALENDAR

	ACTIVITY	MONTHS																		Deliverables/Milestones
		March 22	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Jan 23	Feb	March	Apr	May	Jun	Jul	Aug	
		M 1	M 2	M 3	M 4	M 5	M 6	M 7	M 8	M 9	M 10	M 11	M 12	M 13	M 14	M 15	M 16	M 17	M 18	
WP1_SO1	Task 1.1					D1.1 I1		I2					I3							D1.1 ERN-EuroBloodNet development strategy
	Task 1.2	I4,5,6							I7					MS1 I8,9						MS1 Board of Network meeting
	Task 1.3																		MS2	MS2 Final report
WP2_SO2	Task 2.1			I10, 11		D2.1													D2.3 I12	D2.1 ERN-EuroBloodNet Dissemination plan D2.2 ERN-EuroBloodNet Dissemination report
	Task 2.2			MS3 I16	I13			I14	I17										I15,18	MS3 Update of dissemination and communication materials
	Task 2.3				I19														MS4 I20,21	MS4 ERN-EuroBloodNet peer review publications
WP3_SO3	Task 3.1					D3.1				I22,23	I24									D3.1 ERN-EuroBloodNet evaluation plan
	Task 3.2		I25				MS5 I26							MS6 I26					MS7 D3.2	MS5,6,7 Internal monitoring exercises I, II, III D3.2 ERN-EuroBloodNet evaluation report
WP4_SO4	Task 4.1													I28	I29				I30	
	Task 4.2																			
	Task 4.3					MS8				I31	I32								D4.1 I33	MS8 Definition of the first Virtual Boards participating in pilot scheme

D: Deliverable
 MS: Milestone
 I: Indicator
 WP: Working Package
 SO: Specific Objective
 M: Month

	ACTIVITY	MONTHS																		Deliverables/Milestones
		March 22	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Jan 23	Feb	March	Apr	May	Jun	Jul	Aug	
		M 1	M 2	M 3	M 4	M 5	M 6	M 7	M 8	M 9	M 10	M 11	M 12	M 13	M 14	M 15	M 16	M 17	M 18	
WP5_SO5	Task 5.1																		MS9	MS9 Query builder for HCPs and experts activity
	Task 5.2	MS10 I34	I35,36											MS11 I34	I35,36	D5.1				MS10,11 ERN monitoring exercise I, II D5.1 ERN-EuroBloodNet report on monitoring
	Task 5.3				MS12 I37				I38										I39	MS12 Conduction of a Mapping exercise on HSP
	Task 5.4		I40			MS13 I41													I42	MS13 Online form for Infopoint patients queries
WP5_SO6	Task 5.5																			
	Task 5.6																			
	Task 5.7					I43	I46	I44	I47	MS14	I45								I48	MS14 ENROL pilots data gathering
	Task 5.8			I49	MS15					I50									D5.2 I51	MS15 ENROL Statistical plan D5.2 ENROL statistical analysis
	Task 5.9				MS16															MS16 Statistical analysis of RBC and Covid-19 patients data
WP6_SO7	Task 6.1																		D6.1	D6.1 ERN-EuroBloodNet report on educational actions
	Task 6.2																		MS17	MS17 ERN-EuroBloodNet eLearning educational environment expanded
	Task 6.3													MS18					I52,53, 54,55,	MS18 Definition of new webinars programs for health professionals
	Task 6.4		MS19																I59,60, 61,62,	MS19 Definition of new webinars programs for patients
	Task 6.5			MS21 I66	I67		I68													MS20 Definition of Preceptorship program
	Task 6.6				I69				MS21 I70	I71										MS21 Co-organization with ePAGs of session at ASCAT 2023
WP6_SO8	Task 6.7			I72		I73	MS22 I74													MS22 Public repository updated with Bleeding and lymphoid subnetworks
	Task 6.8				MS23	I75				I76									D6.2 I77	MS23 Consensus conference for Adult Burkitt Lymphoma Guideline D6.2 ERN-EuroBloodNet report on CPGs and other CDMTs
	Task 6.9						I78					M24				I79			I80	MS24 Patients pathway conference



https://ec.europa.eu/health/ern_en



www.eurobloodnet.eu

Co-funded by the European Union

